VolitionRx Ltd Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Research And Development Expenses	$ 4,650,658	$ 4,002,212	$ 15,007,623	$ 11,202,902
Terms of license Agreement			Belgian Volition received an upfront payment of $10.0 million in 2022, and is eligible to receive further milestone payments of (i) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC screening test for Canine Lymphoma & HSA, (ii) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC monitoring test for the same conditions, and (iii) $5.0 million upon the first commercial sale by or on behalf of Heska of a screening or monitoring test for lymphoma in felines
Cash and cash equivalents	10,808,747		$ 10,808,747		$ 10,867,050
Accounts receivable	$ 34,441		$ 34,441		$ 72,609
Warrants And Options [Member]
Potentially Dilutive Securities Excluded From The Computation Of Eps	9,151,605		9,151,605
Cash and cash equivalent [Member]
Cash and cash equivalents	$ 10,800,000		$ 10,800,000
Research And Development Expenses [Member]
Research And Development Expenses			$ 15,000,000.0	$ 11,200,000